Search for: "In Re Nortel Networks Corp. Securities Litigation"
Results 1 - 11
of 11
Sorted by Relevance
|
Sort by Date
27 Aug 2008, 1:00 pm
The Second, Fifth and Eleventh Circuits have issued some interesting class-action-related opinions in recent weeks: In In re: Nortel Networks Corp. [read post]
30 Jan 2007, 12:29 pm
(In re: Nortel Networks Corp. [read post]
25 Sep 2008, 12:13 pm
” In re Nortel Networks Corp. [read post]
21 Aug 2008, 12:01 pm
” In re Nortel Networks Corp. [read post]
27 Mar 2023, 9:01 pm
We examine developments in federal securities litigation involving special purpose acquisition companies. [read post]
22 Mar 2012, 5:00 am
In Re Nortel, the Ontario Ministry of the Environment proposed to use Directors’ Orders to force Nortel to spend at least $18 million on investigating and remediating chlorinated solvent contamination on properties long since sold, and no longer used by Nortel. [read post]
19 Aug 2008, 7:33 pm
" In re Nortel Networks Corp. [read post]
10 Jun 2015, 3:49 pm
Facebook, Inc., 2014 BCSC 953 Licensing/Technology Contracting Nortel Networks Corporation (Re) 2015 ONSC 2987 In re: NORTEL NETWORKS, INC., Case No. 09-10138 (D.Del. [read post]
13 Aug 2019, 10:23 am
(American Airlines), In re Dewey & LeBoeuf LLP, In re Eastman Kodak Company, and In re Nortel Networks Inc. [read post]
25 Jul 2008, 7:04 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: CAFC affirms validity and enforceability of Eisai’s compound patent on Aciphex; elucidates current standard for obviousness of chemical composition of matter patents: Eisai v Reddy’s Lab’s and Teva Pharma: (Orange Book Blog), (Patent Docs), (Patent Prospector), (IP Law360), (Hal Wegner), (Patent Baristas), Three-strikes scheme… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]
